Medicare's new $2,000 drug cap: what it does, and what the evidence shows

Since 1 January 2025, Medicare limits what any Part D enrollee pays out of pocket for prescription drugs to $2,000 in a year — the first hard ceiling in the drug benefit's history [s1]. Independent modeling suggests the change is far from symbolic: more than a million older adults with cardiovascular risk factors alone were spending above that line, with combined savings estimated at roughly $1.7 billion a year for that group [s3].

What actually changed

The cap is the last step of a redesign of the Part D benefit written into the Inflation Reduction Act of 2022 [s1]. Before it, the benefit had no true out-of-pocket maximum: enrollees who reached the "catastrophic" phase of coverage still owed 5 percent of their drug costs indefinitely, which for someone on an expensive specialty drug could run to many thousands of dollars a year. The redesign removed that 5 percent coinsurance in 2024 and then, in 2025, set the annual out-of-pocket threshold at $2,000, indexed to rise in later years [s1]. Once an enrollee's spending hits the threshold, the plan covers the rest for the year.

The reform also created a second, less-noticed feature: the Medicare Prescription Payment Plan, formally the Maximum Monthly Cap on Cost-Sharing Payments Program, established by section 11202 of the IRA [s1]. It lets enrollees spread their out-of-pocket costs across monthly installments instead of paying a large sum at the pharmacy counter — a response to the fact that drug costs are lumpy, often concentrated in a single fill early in the year [s1]. The operating rules for that program were codified in the Contract Year 2026 Medicare rule [s2].

Who it reaches

A cap only helps people who would otherwise blow past it, and most enrollees do not. The best public estimate of who does comes from a study in the Journal of the American College of Cardiology, which modeled the reform against a large, defined population: Medicare beneficiaries aged 65 and older with at least one cardiovascular risk factor or condition [s3].

Of an estimated 34 million such beneficiaries, about 1,020,484 had out-of-pocket drug costs above $2,000 a year [s3]. For those already over the line, the authors put the median out-of-pocket saving at $855 a year and total annual savings at roughly $1.7 billion [s3]. A further 1,289,861 beneficiaries would become newly eligible for the program's full low-income subsidy, which the IRA expanded [s3].

The study's limits are worth stating. It is a pre-implementation projection built on 2016–2019 data, and it looks at one clinical group — people with heart-disease risk — rather than the whole Part D population, so it is a slice of the effect, not the total [s3]. But it establishes the order of magnitude: the cap is not a rounding error for the people who hit it.

What the evidence does and doesn't tell us

High out-of-pocket drug costs are linked to financial strain, skipped or stretched prescriptions, and worse outcomes — the background rationale the cardiology study opens with [s3]. There is a broad and consistent body of evidence that lowering what patients pay improves whether they take their medicines. What does not yet exist is direct evidence that this specific cap improves health, because the outcomes it might change — fewer skipped statins, fewer avoidable hospitalizations — take years to measure and the policy is barely a year old. The savings are quantifiable now; the health payoff is a hypothesis the coming data will test.

There are also open questions on the other side of the ledger. Plans facing a firm liability cap can respond by raising premiums, tightening formularies, or adding utilization controls, any of which shifts the burden rather than removing it. And the monthly-payment option only helps if enrollees know it exists and opt in, which early on many did not.

Where it fits

The $2,000 cap is one piece of a larger set of IRA drug provisions that also let Medicare negotiate prices on selected drugs for the first time. It addresses a different problem from the one that makes US list prices the highest in the world: the cap does nothing to lower a drug's price, only what a patient pays at the counter — which is also why price caps on specific products, as with insulin, can coexist with high underlying costs.

What to watch

Whether uptake of the monthly Prescription Payment Plan rises as awareness grows, how the indexed threshold climbs in future years, and whether early data show the cap translating into better adherence rather than just lower bills.